<p>瑞银资产管理（UBS AM）是瑞银资产管理美洲有限公司（UBS ASSET MANAGEMENT AMERICAS LLC）的一家独立业务单位，根据其最近向证券交易委员会（SEC）提交的 13F 表格，在第四季度将其在 Twist Bioscience Co.（纳斯达克代码：TWST - 免费报告）的持股比例减少了 3.0%。该机构投资者在此期间出售了 26,524 股后，持有该公司 853,675 股股票。瑞银资产管理在最近的报告期末持有 Twist Bioscience 1.43% 的股份，价值 39,670,000 美元。</p>
<p>获取 <strong>Twist Bioscience</strong> 警报：</p>
<p>其他几家机构投资者最近也增加或减少了在 TWST 的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在 Twist Bioscience 的持股增加了 3.4%。先锋集团目前持有 5,807,183 股该公司股票，价值 269,860,000 美元，此前在上个季度又购买了 189,791 股。ARK 投资管理（ARK Investment Management LLC）在第四季度将其在 Twist Bioscience 的持股增加了 4.4%。ARK 投资管理目前持有 5,595,865 股该公司股票，价值 260,040,000 美元，此前在上个季度又购买了 237,772 股。Thrivent Financial for Lutherans 在第四季度将其在 Twist Bioscience 的持股增加了 54.6%。Thrivent Financial for Lutherans 目前持有 1,505,753 股该公司股票，价值 69,972,000 美元，此前在上个季度又购买了 532,040 股。Geode Capital Management LLC 在第四季度将其在 Twist Bioscience 的持股增加了 0.5%。Geode Capital Management LLC 目前持有 1,374,667 股该公司股票，价值 63,895,000 美元，此前在上个季度又购买了 6,908 股。最后，First Light Asset Management LLC 在第四季度购买了 Twist Bioscience 的新股份，价值 56,984,000 美元。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师对 TWST 股票发表了看法。斯科舍银行（Scotiabank）在 2 月 4 日的研究报告中重申了对 Twist Bioscience 股票的 “跑赢大盘” 评级。古根海姆（Guggenheim）在 5 月 6 日的研究报告中重申了 “买入” 评级，并将 Twist Bioscience 的目标价设定为 50.00 美元。摩根大通（JPMorgan Chase &amp; Co.）在 5 月 6 日的研究报告中将 Twist Bioscience 的目标价从 40.00 美元下调至 33.00 美元，并对该公司设定了 “减持” 评级。高盛集团（The Goldman Sachs Group）在 5 月 6 日的研究报告中将 Twist Bioscience 的目标价从 55.00 美元下调至 48.00 美元，并对该公司设定了 “买入” 评级。最后，巴克莱（Barclays）在 4 月 10 日的研究报告中将 Twist Bioscience 的目标价从 58.00 美元下调至 45.00 美元，并对该公司设定了 “增持” 评级。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，八位给予了买入评级。根据 MarketBeat.com 的数据，Twist Bioscience 目前的共识评级为 “适度买入”，平均目标价为 50.40 美元。</p>
<p><strong>查看我们最新的 TWST 股票报告</strong></p>
<h2>Twist Bioscience 股票上涨 0.4%</h2>
<p>Twist Bioscience 的股票在周一开盘价为 28.26 美元。该公司的 50 日简单移动平均线为 36.71 美元，200 日简单移动平均线为 42.81 美元。该公司的市值为 16.9 亿美元，市盈率为-8.36，贝塔值为 2.54。该公司的债务与股本比率为 0.03，速动比率为 4.62，流动比率为 4.96。Twist Bioscience Co.的股价在过去一年中最低为 27.12 美元，最高为 60.90 美元。</p>
<p>Twist Bioscience（纳斯达克代码：TWST - 获取免费报告）最近于 5 月 5 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.66 美元，低于市场共识预期的-0.56 美元，差额为-0.10 美元。该公司季度收入为 9279 万美元，而市场共识预期为 9200 万美元。Twist Bioscience 的股本回报率为-32.69%，净利润率为-59.76%。作为一个整体，股票分析师预计 Twist Bioscience Co.在当前年度的每股收益将为-2.12 美元。</p>
<h2>Twist Bioscience 的内部活动</h2>
<p>在相关消息中，首席执行官 Emily M. Leproust 于 5 月 21 日星期三出售了 2802 股该股票。股票以平均价格 29.75 美元出售，总价值为 83,359.50 美元。交易完成后，首席执行官现在持有该公司 649,630 股股票，价值 19,326,492.50 美元。这代表其持股比例减少了 0.43%。该出售在向 SEC 的备案中披露，相关文件可在此链接查看。此外，首席运营官 Patrick John Finn 于 5 月 21 日星期三出售了 1877 股该股票。股票以平均价格 29.75 美元出售，总交易额为 55,840.75 美元。交易完成后，首席运营官现在持有该公司 240,783 股股票，价值 7,163,294.25 美元。这代表其持股比例减少了 0.77%。该出售的披露信息可以在这里找到。内部人士在过去 90 天内出售了价值 951,499 美元的 26,011 股公司股票。公司内部人士持有该公司 3.01% 的股份。</p>
<h2>Twist Bioscience 公司简介</h2>
<p>（免费报告）</p>
<p>Twist Bioscience Corporation 从事合成 DNA 产品的制造和销售。该公司提供用于治疗、诊断、化学/材料、食品/农业、数据存储以及生物技术、制药、工业化学和农业公司以及学术实验室的各种应用的合成基因和基因片段；用于靶向 NGS、CRISPR 基因编辑、诱变实验、DNA 折纸、DNA 计算、DNA 中的数据存储及其他应用的寡核苷酸池；以及专注于药物发现和开发的客户所需的免疫球蛋白 G 蛋白。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而非 Twist Bioscience</li>
<li>便士股票适合你的投资组合吗？</li>
<li>这次市场抛售可能会引发对百事可乐的价值轮换</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>Alphabet 股票表现滞后——但 Waymo 可能是其隐藏的驱动因素</li>
<li>如何购买黄金股票并投资黄金</li>
<li>Trade Desk 驳斥批评者；复苏看起来有望继续</li>
</ul>
<p><strong>想看看其他对 TWST 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Twist Bioscience Co. (NASDAQ:TWST - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFdTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Twist Bioscience 吗？</h2>
<p>在考虑 Twist Bioscience 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Twist Bioscience 并不在名单上。</p>
<p>虽然 Twist Bioscience 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TWST

<p>瑞士银行资产管理美洲有限公司在第四季度将其在 Twist Bioscience Co.（纳斯达克代码：TWST）的持股减少了 3.0%，目前持有 853,675 股，价值 3967 万美元。其他投资者如先锋集团和 ARK 投资管理公司则增加了他们的持股。分析师对 TWST 的评级褒贬不一，普遍评级为 “适度买入”，平均目标价为 50.40 美元。Twist Bioscience 的股票开盘价为 28.26 美元，市值为 16.9 亿美元。该公司报告的季度每股收益为（0.66 美元），未达到预期，预计本年度每股收益为-2.12 美元</p>

<p>UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 3.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 853,675 shares of the company's stock after selling 26,524 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.43% of Twist Bioscience worth $39,670,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>瑞银资产管理（UBS AM）是瑞银资产管理美洲有限公司（UBS ASSET MANAGEMENT AMERICAS LLC）的一家独立业务单位，根据其最近向证券交易委员会（SEC）提交的 13F 表格，在第四季度将其在 Twist Bioscience Co.（纳斯达克代码：TWST - 免费报告）的持股比例减少了 3.0%。该机构投资者在此期间出售了 26,524 股后，持有该公司 853,675 股股票。瑞银资产管理在最近的报告期末持有 Twist Bioscience 1.43% 的股份，价值 39,670,000 美元。</p>
</div><p>Get <strong>Twist Bioscience</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Twist Bioscience</strong> 警报：</p>
</div><p>Several other institutional investors have also recently added to or reduced their stakes in TWST. Vanguard Group Inc. increased its stake in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after purchasing an additional 189,791 shares during the last quarter. ARK Investment Management LLC increased its stake in Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after purchasing an additional 237,772 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after purchasing an additional 532,040 shares during the last quarter. Geode Capital Management LLC increased its stake in Twist Bioscience by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock valued at $63,895,000 after purchasing an additional 6,908 shares during the last quarter. Finally, First Light Asset Management LLC bought a new stake in Twist Bioscience during the fourth quarter valued at $56,984,000.</p>
<div class="lb-trans"><p>其他几家机构投资者最近也增加或减少了在 TWST 的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在 Twist Bioscience 的持股增加了 3.4%。先锋集团目前持有 5,807,183 股该公司股票，价值 269,860,000 美元，此前在上个季度又购买了 189,791 股。ARK 投资管理（ARK Investment Management LLC）在第四季度将其在 Twist Bioscience 的持股增加了 4.4%。ARK 投资管理目前持有 5,595,865 股该公司股票，价值 260,040,000 美元，此前在上个季度又购买了 237,772 股。Thrivent Financial for Lutherans 在第四季度将其在 Twist Bioscience 的持股增加了 54.6%。Thrivent Financial for Lutherans 目前持有 1,505,753 股该公司股票，价值 69,972,000 美元，此前在上个季度又购买了 532,040 股。Geode Capital Management LLC 在第四季度将其在 Twist Bioscience 的持股增加了 0.5%。Geode Capital Management LLC 目前持有 1,374,667 股该公司股票，价值 63,895,000 美元，此前在上个季度又购买了 6,908 股。最后，First Light Asset Management LLC 在第四季度购买了 Twist Bioscience 的新股份，价值 56,984,000 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts have weighed in on TWST shares. Scotiabank reiterated an &#34;outperform&#34; rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Guggenheim reiterated a &#34;buy&#34; rating and set a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. JPMorgan Chase &amp; Co. lowered their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an &#34;underweight&#34; rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group lowered their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, May 6th. Finally, Barclays lowered their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, April 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $50.40.</p>
<div class="lb-trans"><p>几位分析师对 TWST 股票发表了看法。斯科舍银行（Scotiabank）在 2 月 4 日的研究报告中重申了对 Twist Bioscience 股票的 “跑赢大盘” 评级。古根海姆（Guggenheim）在 5 月 6 日的研究报告中重申了 “买入” 评级，并将 Twist Bioscience 的目标价设定为 50.00 美元。摩根大通（JPMorgan Chase &amp; Co.）在 5 月 6 日的研究报告中将 Twist Bioscience 的目标价从 40.00 美元下调至 33.00 美元，并对该公司设定了 “减持” 评级。高盛集团（The Goldman Sachs Group）在 5 月 6 日的研究报告中将 Twist Bioscience 的目标价从 55.00 美元下调至 48.00 美元，并对该公司设定了 “买入” 评级。最后，巴克莱（Barclays）在 4 月 10 日的研究报告中将 Twist Bioscience 的目标价从 58.00 美元下调至 45.00 美元，并对该公司设定了 “增持” 评级。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，八位给予了买入评级。根据 MarketBeat.com 的数据，Twist Bioscience 目前的共识评级为 “适度买入”，平均目标价为 50.40 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on TWST</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 TWST 股票报告</strong></p>
</div><h2>Twist Bioscience Stock Up 0.4%</h2>
<div class="lb-trans"><h2>Twist Bioscience 股票上涨 0.4%</h2>
</div><p>Twist Bioscience stock opened at $28.26 on Monday. The company has a 50-day simple moving average of $36.71 and a 200-day simple moving average of $42.81. The firm has a market capitalization of $1.69 billion, a P/E ratio of -8.36 and a beta of 2.54. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a one year low of $27.12 and a one year high of $60.90.</p>
<div class="lb-trans"><p>Twist Bioscience 的股票在周一开盘价为 28.26 美元。该公司的 50 日简单移动平均线为 36.71 美元，200 日简单移动平均线为 42.81 美元。该公司的市值为 16.9 亿美元，市盈率为-8.36，贝塔值为 2.54。该公司的债务与股本比率为 0.03，速动比率为 4.62，流动比率为 4.96。Twist Bioscience Co.的股价在过去一年中最低为 27.12 美元，最高为 60.90 美元。</p>
</div><p>Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. As a group, equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.</p>
<div class="lb-trans"><p>Twist Bioscience（纳斯达克代码：TWST - 获取免费报告）最近于 5 月 5 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.66 美元，低于市场共识预期的-0.56 美元，差额为-0.10 美元。该公司季度收入为 9279 万美元，而市场共识预期为 9200 万美元。Twist Bioscience 的股本回报率为-32.69%，净利润率为-59.76%。作为一个整体，股票分析师预计 Twist Bioscience Co.在当前年度的每股收益将为-2.12 美元。</p>
</div><h2>Insider Activity at Twist Bioscience</h2>
<div class="lb-trans"><h2>Twist Bioscience 的内部活动</h2>
</div><p>In related news, CEO Emily M. Leproust sold 2,802 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $83,359.50. Following the completion of the transaction, the chief executive officer now owns 649,630 shares in the company, valued at $19,326,492.50. This represents a 0.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Patrick John Finn sold 1,877 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $55,840.75. Following the completion of the transaction, the chief operating officer now owns 240,783 shares of the company's stock, valued at $7,163,294.25. This represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,011 shares of company stock worth $951,499 in the last 90 days. Corporate insiders own 3.01% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Emily M. Leproust 于 5 月 21 日星期三出售了 2802 股该股票。股票以平均价格 29.75 美元出售，总价值为 83,359.50 美元。交易完成后，首席执行官现在持有该公司 649,630 股股票，价值 19,326,492.50 美元。这代表其持股比例减少了 0.43%。该出售在向 SEC 的备案中披露，相关文件可在此链接查看。此外，首席运营官 Patrick John Finn 于 5 月 21 日星期三出售了 1877 股该股票。股票以平均价格 29.75 美元出售，总交易额为 55,840.75 美元。交易完成后，首席运营官现在持有该公司 240,783 股股票，价值 7,163,294.25 美元。这代表其持股比例减少了 0.77%。该出售的披露信息可以在这里找到。内部人士在过去 90 天内出售了价值 951,499 美元的 26,011 股公司股票。公司内部人士持有该公司 3.01% 的股份。</p>
</div><h2>Twist Bioscience Company Profile</h2>
<div class="lb-trans"><h2>Twist Bioscience 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.</p>
<div class="lb-trans"><p>Twist Bioscience Corporation 从事合成 DNA 产品的制造和销售。该公司提供用于治疗、诊断、化学/材料、食品/农业、数据存储以及生物技术、制药、工业化学和农业公司以及学术实验室的各种应用的合成基因和基因片段；用于靶向 NGS、CRISPR 基因编辑、诱变实验、DNA 折纸、DNA 计算、DNA 中的数据存储及其他应用的寡核苷酸池；以及专注于药物发现和开发的客户所需的免疫球蛋白 G 蛋白。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Twist Bioscience</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>This Market Sell-Off Might Trigger a Value Rotation Into Pepsi</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Alphabet Stock Lags—But Waymo May Be Its Hidden Driver</li>
<li>How to Buy Gold Stock and Invest in Gold</li>
<li>Trade Desk Silences Critics; Recovery Looks Poised to Continue</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Twist Bioscience</li>
<li>便士股票适合你的投资组合吗？</li>
<li>这次市场抛售可能会引发对百事可乐的价值轮换</li>
<li>什么是债券市场假期？如何投资和交易</li>
<li>Alphabet 股票表现滞后——但 Waymo 可能是其隐藏的驱动因素</li>
<li>如何购买黄金股票并投资黄金</li>
<li>Trade Desk 驳斥批评者；复苏看起来有望继续</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TWST?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 TWST 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Twist Bioscience Co. (NASDAQ:TWST - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TWST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Twist Bioscience Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Twist Bioscience 吗？</h2>
</div><p>Before you consider Twist Bioscience, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Twist Bioscience 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Twist Bioscience 并不在名单上。</p>
</div><p>While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Twist Bioscience 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Twist Bioscience 公司（NASDAQ:TWST）的股票被 UBS AM 出售，UBS 资产管理美洲有限责任公司旗下的一个独立业务部门